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Tumour ablation by resection, when feasible, is the treatment
of choice for most patients with primary hepato-biliary
tumours and secondary malignancies of colo-rectal origin
(Iwatsuki & Starzl, 1988a). As a result of the use of tumour
markers in the populations at risk and an increased use of
accurate non-invasive imaging techniques, improved detec-
tion of smaller lesions within the parenchyma or hilum has
occurred and this has led to a higher resectability rate
(Okuda & Ishak, 1987), although this rarely exceeds 30-40%
(Bismuth et al., 1986). Furthermore, a multidisciplinary
approach, improvements in patient selection and manage-
ment, and refined techniques in liver surgery, have contri-
buted both to a lower perioperative mortality and improved
long-term survival rates (Tang, 1985).
For small primary hepatocellular carcinomas, follow-up of
144 patients, who underwent resection, showed a 5-year sur-
vival of 63.2% (Tang et al., 1989). The best results were
found in patients with a tumour of less than 2 cm and those
with an encapsulated tumour. Similar results were found in a
French-Italian cooperative study of 72 patients with cirrhosis
(Franco et al., 1990). However, where the tumour is bilobar
or central, where there is vascular invasion, or if the remain-
ing parenchyma is severely compromised from cirrhosis, sub-
total hepatectomy may not be an option. In this situation,
the median post-operative survival is only 2 to 4 months.
For patients whose disease is not resectable by conven-
tional approaches, a total hepatectomy and subsequent liver
replacement may offer the only true chance for survival,
although in practice only about one quarter of patients refer-
red to transplant centres will be suitable (Ismail et al., 1990).
Hepatocellular carcinoma (HCC)
The value of liver replacement for HCC is still the subject of
much controversy. The European Liver Transplant registry,
with results from 32 European centres, reported a 2-year
actuarial survival rate of 30% in 217 patients who underwent
liver replacement for HCC (Bismuth et al., 1987). Centres in
Hannover, King's College/Cambridge and Pittsburgh report
similar 3-year survival rates of about 20% and the King's
College/Cambridge group report some limited early success
with subsequent chemotherapy (Ringe et al., 1989; O'Grady
et al., 1988; Koneru, 1988).
Iwatsuki et al. (1989) have described the prognostic indi-
cators affecting survival and recurrence after transplantation.
In a group of 80 liver recipients with HCC, the tumour size
(greater than 5 cm), multiple nodules, vascular invasion and
tumour shape (non-circumscribed) were poor prognostic
histopathological factors for recurrence in non-fibrolamellar
HCC. They and others have confirmed the more favourable
prognosis associated with the fibrolamellar variant of HCC,
where the 1-year survival rate was 100% with an overall
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recurrence rate of 50% (O'Grady et al., 1988; Starzl et al.,
1986).
The Hannover group report significant differences in
median survival time for different groups classified according
to TNM (Ringe et al., 1989). Stage II (pT2 pNO pMO)
patients had a median survival of 120 months compared to
11.8 months for stage III (pTl-3 pNO-1 pMO) and 8.75
months for stage IVA (pT4 pNO-1 pMO). All patients group-
ed as stage IVB (pT1-4 pNO-1 pMl) died within 2 months. In
this series pre-operative serum alpha-fetoprotein levels did
not have a significant correlation with post-operative out-
come. However tumour-free long-term survivors were noted
to have normal or only slightly elevated alpha-fetoprotein
levels before liver replacement. For these patients, coexistence
of cirrhosis did not influence the long-term survival rate but
the 30-day mortality was higher in the cirrhotic patients.
However, of the ten patients transplanted for coexistent cirr-
hosis and HCC in Birmingham, none survived more than 1
year (Ismail et al., 1990).
Carcinoma of the biliary tract
The prognosis following liver replacement for tumours of the
biliary tract is uniformly poor. Peripheral cholangiocarcin-
omas appear incurable by this approach as widespread dis-
tant metastases developed in all eight patients surviving more
then 30 days in the Hannover series (Ringe et al., 1989).
Similarly six of seven patients in the King's College/Cam-
bridge series developed recurrence of tumour (the remaining
patient died at 4 months following a cerebro-vascular acci-
dent) (O'Grady et al., 1988).
Slightly more encouraging results are found in patients
with central lesions. The Hannover group report on 20
patients and found the major influence on survival time was
the lymph node status (Ringe et al., 1989). Of the node
negative recipients, eight of 13 were alive (median survival
35 months) and the overall 2-year actuarial survival rate was
64.1%. All seven patients with regional lymph node metas-
tases, however, had a much more limited survival span
(median survival 7 months). However, of the 13 liver trans-
plants performed in King's College/Cambridge for central
cancers, only seven patients survived 3 months and 6 died of
recurrence of tumour (median survival 8.5 months). The
remaining patient was alive and well at 6.5 years (O'Grady et
al., 1988). In a series of nine patients from Pittsburgh, Iwat-
suki reported that no patient with bile duct cancer had lived
2 years post-operatively (Iwatsuki et al., 1988b).
There is no doubt that accurate staging of the tumour is
vital before transplantation and many centres routinely per-
form an exploratory laparotomy with lymph node sampling.
The value of such a procedure has to be balanced against an
increased risk to the patient and the disadvantage of interfer-
ing at the site of transplant.
Some hope for these patients can be drawn from reported
results of a series of six bile duct carcinomas treated by
'abdominal cluster' operations (Starzl et al., 1989). The oper-
ation consists of the removal of the liver, stomach, spleen,
pancreas, duodenum, proximal jejunum, terminal ileum, and
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ascending and transverse colon. The organs are replaced by
cadaveric organ cluster grafts that include the liver, pancreas,
duodenum and variable amounts of proximal jejunum. None
of the eight patients alive 3 to 9 months post-operatively had
proven recurrent tumour; however it is obviously too early to
judge the medium- and long-term effects of this radical pro-
cedure on the disease process. The technique has subse-
quently been modified to remove the need for the pancreatic
and jejunal grafts. Pancreatic islet grafts have been success-
fully seeded within the hepatic graft, either from the original
or a third party donor (Tzakis et al., 1990).
Other primary liver tumours
A large group of other primary tumours of the liver have
been treated by liver replacement. However, the total
numbers of each are still small, making a judgement on the
role of transplantation for these tumours more difficult. Most
are epithelioid haemangioendotheliomas, angiosarcomas, and
hepatoblastomas. In a series of five primary angiosarcomas
at King's College/Cambridge, four died within the first 2
months and the fifth had a tumour recurrence at 6 months
(O'Grady et al., 1988). In Pittsburgh, seven patients with
haemangioendothelioma were treated by liver transplantation
(Koneru, 1989). One patient died of recurrence at 16 months
and the remaining six were reported alive. In a combined
series of ten centres in North America, 12 children with
hepatoblastoma were treated by liver replacement. Half of
these children remained alive 24 to 70 months following
transplantation (Koneru et al., 1991).
Secondary tumours
A series ofnine patients with liver metastases underwent liver
replacement by the Hannover group (Ringe et al., 1989).
Four patients died within 30 days due to complications
unrelated to the malignant disease. Four others died of
tumour recurrence or residual tumour, all within 10 months.
The remaining patient was alive at 4 months following her
transplant for multiple liver metastases from a neuroendo-
crine malignoma producing growth hormone releasing factor,
the primary having been removed from the jejunum 3 years
previously. Mulbacher and Piza (1987) have reported their
experience of ten liver transplants for colorectal metastases.
They found a 68% 1-year survival and had two 3-year
survivors, one of whom remained free of detectable tumour.
They argue that liver transplantation for liver metastases
provides acceptable mid-term results with excellent quality of
life, which for a long period is unaffected by recurrence of
disease.
In an attempt to improve the generally poor prognosis
following liver replacement for metastases, multimodality
therapy is logical. A combination of liver and bone marrow
replacement, cytotoxic drugs and total body irradiation have
been applied to patients with advanced breast cancer. The
results are disappointing, with only one long-lasting remis-
sion and no cures among six patients (Margreiter et al., 1985,
1987).
Abdominal organ cluster operations are a potential thera-
peutic option for patients with primary malignancy of the
stomach or duodenum and with secondary involvement of
the liver (Starzl et al., 1989). However it is too early to make
a comment on the effect of these operations on long-term
survival and palliation.
Slightly more encouraging results in liver replacement for
metastatic disease have been found in the management of
metastatic apudomas. The Pittsburgh group have reported
their experience in liver replacement in five patients with
unresectable hepatic metastases arising from endocrine
tumours ofgastrointestinal origin (Makowka et al., 1989). Of
these patients, one died 2 months post-operatively of rejec-
tion and graft failure, and two died of tumour recurrence at
9 months (of concomitant cholangiocarcinoma detected at
operation) and 10 months respectively. The remaining two
patients were clinically and radiologically disease-free at 41
and 23 months after hepatic transplantation. Both patients
had a primary glucagonoma and one underwent a distal
pancreatectomy and splenectomy at the time of the trans-
plantation to resect the primary. Bramley et al. (1990) report-
ed successful hepatic replacement and partial pancreatectomy
in a patient with metastatic vipoma, who passed up to 9 litres
of diarrhoeal fluid daily. The patient is clinically well with no
evidence of tumour recurrence on imaging or serum VIP
levels 18 months post-transplantation.
Conclusion
The factors which play a major prognostic role following
liver transplantation for malignancy are not well determined
and it remains difficult to predict those patients who are most
likely to have prolonged survival without tumour recurrence.
At present, however, there are two well recognised exceptions
to the generally poor prognosis of liver transplantation in
cancer patients: incidental hepatomas arising in livers with
other diseases and often only discovered at operation, and
the fibrolamellar variant of hepatocellular carcinoma (Starzl
et al., 1986).
The results of liver replacement for metastatic disease are
far from encouraging and this treatment has been abandoned
in many centres as a disappointing, unrewarding experience.
However thert may be a role for hepatic transplantation in
selected patients with tumours of low grade malignancy. The
role of adjuvant chemotherapy for these patients has as yet
received relatively little attention. It is possible that a com-
bined approach could lead to improved results but the
combination of immunosuppression with chemotherapy and
immunotherapy is uncharted at this time.
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